Author

Bingyu Li

Observed names: B. T. Li, B.T. Li

Institutions: Mount Sinai Hospital, Xinjiang Medical University, Tumor Hospital of Xinjiang Medical University

Observed institutions: Tongji University, Mount Sinai Hospital, Memorial Sloan Kettering Cancer Center, University of Wisconsin–Madison, Xinjiang Medical University, UW Health University Hospital, Tumor Hospital of Xinjiang Medical University, Weill Cornell Medicine, Icahn School of Medicine at Mount Sinai

ORCID: 0000-0002-9222-951X

Observed ORCID: 0000-0002-9222-951X

OpenAlex ID: A5080998623

Chemotherapy remains an essential element of personalized care for persons with lung cancers

2016 · M.D. Hellmann, B.T. Li, et al. · Annals of Oncology · 136

Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine

2024 · Bingyu Li, Qiong Zhang, et al. · Biomedicines · 38

Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers

2021 · J. Wu, D. Liu, et al. · Investigational New Drugs · 30

An Update of Immunohistochemistry in Hepatocellular Carcinoma

2025 · Bingyu Li, Larry Huang, et al. · Diagnostics · 13

TP53 mutation promotes sunitinib resistance in gallbladder cancer via the ARHGEF7-AS2/miR-326/AXL pathway

2026 · Linhua Yang, Ming Zhan, et al. · Acta Pharmaceutica Sinica B

METTL5-mediated rRNA modification controls prostate cancer progression through the IRF7/DNA2 axis and mitophagy regulation

2026 · Ruifeng Yang, Qintao Ge, et al. · Oncogene

Correction: GRB2 promotes brain metastasis in HER2-positive breast cancer by regulating the Ras/MAPK pathway

2026 · Hongyu Li, Yalin Zhang, et al. · Scientific Reports

Works count: 7

Citation count: 217

H-index: 4

I10-index: 4